Ushbu ish iqtibos qilgan ishlar

55 ta ish

Ish: Exploring Cellular Immunotherapy Platforms in Multiple Myeloma

Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9
Sharh maqola201811 iqtibos
ABI
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao +3
Sharh maqola20236 iqtibos
ABI
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
Maqola20224 iqtibos
ABI
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12
Maqola20213 iqtibos
ABI
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianjun Chu, Youcai Deng, D.M. Benson +13
Maqola20133 iqtibos
ABI
<i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8
Maqola20073 iqtibos
ABI
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert +4
Sharh maqola20153 iqtibos
ABI
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Joseph D. Malaer, Porunelloor A. Mathew
Maqola20173 iqtibos
ABI
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang +3
Sharh maqola20203 iqtibos
ABI
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman, Joshua Richter, Ajai Chari
Sharh maqola20203 iqtibos
ABI
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2
Sharh maqola20213 iqtibos
ABI
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Ben Creelan, Chao Wang, Jamie K. Teer +23
Maqola20213 iqtibos
ABI
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han +2
Sharh maqola20223 iqtibos
ABI
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
Feifei Li, Sheng Liu
Sharh maqola20223 iqtibos
ABI
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
Cheng Sun, Haoyu Sun, Weihua Xiao +2
Sharh maqola20152 iqtibos
ABI
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
Cheng Sun, Haoyu Sun, Cai Zhang +1
Sharh maqola20142 iqtibos
ABI
Are natural killer cells superior CAR drivers?
Hans Klingemann
Maqola20142 iqtibos
ABI
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
Sagar Lonial, Jamie Cavenagh
Sharh maqola20092 iqtibos
ABI
Personalized Dendritic Cell-Based Tumor Immunotherapy
Nona Janikashvili, Nicolas Larmonier, Emmanuel Katsanis
Sharh maqola20092 iqtibos
ABI
Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang, Wenhao Zhang, Peipei Shang +10
Maqola20132 iqtibos
ABI
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
Loek J. Eggermont, Leonie E. Paulis, Jurjen Tel +1
Sharh maqola20142 iqtibos
ABI
Enhancement of Dendritic Cells as Vaccines for Cancer
Meghan E. Turnis, Cliona M. Rooney
Sharh maqola20102 iqtibos
ABI
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Marina Ratta, Francesco Fagnoni, Antonio Curti +9
Maqola20022 iqtibos
ABI
Regulation of Dendritic Cell Migration to the Draining Lymph Node
Alfonso Martin‐Fontecha, Silvia Sebastiani, Uta E. Höpken +4
Maqola20032 iqtibos
ABI
Targeting B-Cell Maturation Antigen in Multiple Myeloma
Yu‐Tzu Tai, Kenneth C. Anderson
Sharh maqola20152 iqtibos
ABI